SAVARA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Savara Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application, which led to significant investor losses during the class period from March 7, 2024, to May 23, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Savara securities during the specified class period [2]. - Investors have until November 7, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that Savara did not disclose that the MOLBREEVI BLA lacked sufficient information, making FDA approval unlikely [4]. Group 2: Impact on Stock Price - On May 27, 2025, Savara announced it received a refusal to file letter from the FDA regarding the MOLBREEVI BLA, causing the stock price to drop by $0.90 per share, or 31.69%, closing at $1.94 per share [5]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is representing the investors and encourages those who suffered losses to contact them for more information [6][7].